 CAMBRIDGE, Mass., Jan. 04, 2022 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq: RUBY, a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM for the treatment of cancer and autoimmune diseases, today announced Pablo J. Cagnoni, M.D., president and chief executive officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 8:15 a.m. ET. 